Servier BioInnovation was founded in February 2018 as the early stage partnering engine of Servier Group, an independent, global pharmaceutical company governed by a non-profit foundation headquartered in France, with subsidiaries in the United States and China.
In early March, six life sciences startups from the Kansai region of Japan, and graduates of CLSI’s FAST Japan: Kansai Fall 2020 program, presented their business plans to over 100 attendees at the Kansai Pitch Demo Day.
Hear about recent updates and innovations from our FAST and CARB-X Companies and CLSA Fellows Members.
As part of our ongoing programs to support early-stage companies, the Spring 2021 FAST Advisory Program just began, providing coaching and business advising for six startups.
The CLSA-CLSI Racial & Social Equity (RSE) Initiative are debuting several new programs and events this summer, offering opportunities for industry professionals to engage with under-represented students and talent.
CLSA’s diverse membership base of life sciences companies and organizations grows each month.
Springer Nature unveils two new, dedicated areas for corporate organizations that specialize in the fields of Biotechnology and Machine Learning.
In addition to STEM education programs run by its partner California Life Sciences Institute, CLSA likes to highlight other innovative STEM programs that are working with our companies to create access to science careers for underserved students. The ICA Cristo Rey Academy is a Dominican Catholic college preparatory school in San Francisco that empowers girls … Continue reading San Francisco’s Cristo Rey Academy
The California Life Sciences Association (CLSA), along with the California Life Sciences Institute (CLSI), would like to thank everyone – members, board members, national organization partners, strategic partners, academic partners and the California life sciences community – for your membership, support and participation throughout the year. As 2019 draws to a close, we’d like to … Continue reading CLSA’s 2019 Year in Review
CLSA Member Insights from King & Spalding: HHS’ Proposals are Designed to Promote Patient Care Coordination, Management, and Efficiencies, and Include Several Points of Interest for Pharmaceutical and Medical Device Manufacturers